Actualités

While Wall Street fretted over the future of its biggest blockbuster, a pair of new drugs were already showing the company's next act was well underway.

ABBV's successful transition beyond Humira and growth from newer medicines give it an edge over MRK in this oncology-immunology showdown.

Houman Ashrafian is leaving Sanofi to pursue a new opportunity. Elsewhere, one of Merck’s prized immune drugs succeeded in a pivotal study and a psychedelics biotech’s shares surged.

Merck (NYSE:MRK) received FDA approval for expanded use of KEYTRUDA and KEYTRUDA QLEX with WELIREG as adjuvant treatment in certain renal cell carcinoma patients. The FDA also granted expanded approval for CAPVAXIVE in children and adolescents at higher risk for pneumococcal disease, making it the only PCV indicated for this US group. Merck and Gilead reported positive Phase 3 data for a once weekly oral HIV treatment regimen. Separately, Merck discontinued a Phase 3 lung cancer trial...

Merck & Co., Inc. (NYSE:MRK) is one of Kevin O’Leary’s top stock picks for 2026 through the O’Shares U.S. Quality Dividend ETF. The stock made up 2.91% of the ETF as of June 17, 2026. On June 12, 2026, Merck said the US FDA approved KEYTRUDA and the easier-to-administer KEYTRUDA QLEX, each with WELIREG, for […]

The Health Care Select Sector SPDR ETF (NYSEARCA:XLV) is having a frustrating year. The fund sits at $149, down about 3% year-to-date while the broader market grinds higher. The good news for XLV holders: the fund has clawed back roughly 14% over the past year, and the 2026 setup looks meaningfully different from the policy ... The 2 Factors That Will Decide Whether XLV Finally Catches the S&P 500 in 2026

While investors fixate on the pipeline, a powerful and accelerating profit stream from its Sanofi collaboration is quietly reshaping the company's financial core.

Pfizer’s recent drug approvals give the company something to build on, with shareholders looking for evidence that cost cuts and newer medicines can keep the 2026 earnings outlook on track.

In the closing of the recent trading day, Merck (MRK) stood at $113.87, denoting a -1.36% move from the preceding trading day.

The market is focused on Amgen's legacy drugs, but one number shows a new, faster-growing core business is already taking over.

U.S. stocks rose in early Thursday trading, rebounding from the previous session’s Fed-driven selloff as falling oil prices and optimism surrounding the Iran peace deal boosted investor sentiment.

BIIB is set to acquire RayThera for up to $1 billion, adding anti-inflammatory candidates that could expand its immunology pipeline and future growth.

GSK wins FDA approval for Utebzi, the first oral carbapenem for complicated UTIs, further expanding its anti-infectives portfolio.

Merck (NYSE:MRK) announced a multi target AI drug discovery collaboration with Protillion Biosciences, focused on high throughput protein engineering for new therapeutics. The agreement includes potential milestone payments tied to progress across multiple discovery programs. Merck also launched a global HPV awareness initiative with Nivi, aimed at emerging markets with high cervical cancer burden. The Nivi partnership uses digital and AI powered health education tools to support HPV...

Management raised the bar, the stock rocketed higher, and now everyone is wondering if this is the new normal or just a sugar high.

Merck & Co., Inc. (NYSE:MRK) is one of the 10 Undervalued Counter Cyclical Stocks to Buy Now. On June 12, 2026, Merck & Co., Inc. (NYSE:MRK) announced that the U.S. Food and Drug Administration approved KEYTRUDA and KEYTRUDA QLEX, each in combination with WELIREG, for the adjuvant treatment of adult patients with renal cell carcinoma […]

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 10 Undervalued Counter Cyclical Stocks to Buy Now. On June 12, 2026, Gilead Sciences, Inc. (NASDAQ:GILD) announced a donation of more than 2,000 vials of its intravenous antiviral therapy, remdesivir, to the Republic of Uganda to support response efforts for the current outbreak of Ebola Bundibugyo virus […]

Moonlake’s lead drug Sonelokimab is being tested across inflammatory conditions, with the biggest near-term focus on hidradenitis suppurativa.

The company is promising a new era of accelerated growth, but the trajectory of one key cancer drug holds a subtle warning for investors.

Management once made manufacturing its top priority; now that the topic has gone quiet, it reveals just how much the company's multi-billion-dollar bet has fundamentally changed.

Gilead Sciences won FDA acceptance for a filing that could expand Yeztugo into a once-weekly oral HIV prevention option, broadening its HIV portfolio.

SpaceX’s $75 billion initial public offering shattered market records, turned founder Elon Musk into the world’s first trillionaire, and opened fresh debates over corporate valuations and governance. It’s not the first time an IPO has shaken things up. IPOs have been reshaping markets since the Bank of North America’s 1783 debut got it all started for the young republic.

Gilead seeks FDA approval for once-weekly oral Yeztugo for HIV prevention, aiming to expand access with a new long-acting PrEP option.

Gain insight on Roche, Zealand Pharma and more in the latest Market Talks covering the health care sector.

AZN shares fell after a camizestrant setback, but blockbuster drugs, oncology growth and a deep pipeline support long-term targets.

They have a habit of consistently raising their payouts.

In the last week, the United States market has stayed flat, yet it has seen a significant increase of 24% over the past year with earnings forecasted to grow by 19% annually. In this context, identifying stocks that are estimated to be undervalued can offer investors potential opportunities for capitalizing on price discrepancies relative to their fair value.

Over the last 7 days, the United States market has remained flat, yet it is up 24% over the past year with earnings anticipated to grow by 19% annually in the coming years. In this context of robust growth expectations, identifying stocks that are trading below their intrinsic value can present opportunities for investors seeking potential long-term gains.

We recently published Jim Cramer Didn’t Hold Back On SpaceX’s IPO & Discussed These 12 Stocks. Johnson & Johnson (NYSE:JNJ) is one of the stocks discussed by Jim Cramer. Johnson & Johnson (NYSE:JNJ)’s shares are up by 53% over the past year and by 15% year-to-date. Leerink Partners discussed the firm on May 13th as […]

While the market fixates on the STELARA patent cliff, the rest of the business is quietly accelerating. Excluding the legacy drug, Johnson & Johnson (JNJ) grew in double digits for the quarter. The Innovative Medicine segment absorbed a massive 920 basis point headwind from STELARA, yet still posted 7.4% growth. This is not a company treading water, but a portfolio already hitting its next stride.